KR102608763B1 - 항-글리코-muc1 항체 및 이의 용도 - Google Patents

항-글리코-muc1 항체 및 이의 용도 Download PDF

Info

Publication number
KR102608763B1
KR102608763B1 KR1020207014390A KR20207014390A KR102608763B1 KR 102608763 B1 KR102608763 B1 KR 102608763B1 KR 1020207014390 A KR1020207014390 A KR 1020207014390A KR 20207014390 A KR20207014390 A KR 20207014390A KR 102608763 B1 KR102608763 B1 KR 102608763B1
Authority
KR
South Korea
Prior art keywords
antibody
seq
glyco
antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207014390A
Other languages
English (en)
Korean (ko)
Other versions
KR20200067885A (ko
Inventor
세이어 화이트
Original Assignee
고 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고 테라퓨틱스, 인크. filed Critical 고 테라퓨틱스, 인크.
Priority to KR1020237040745A priority Critical patent/KR102832078B1/ko
Publication of KR20200067885A publication Critical patent/KR20200067885A/ko
Application granted granted Critical
Publication of KR102608763B1 publication Critical patent/KR102608763B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020207014390A 2017-10-24 2017-10-24 항-글리코-muc1 항체 및 이의 용도 Active KR102608763B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237040745A KR102832078B1 (ko) 2017-10-24 2017-10-24 항-글리코-muc1 항체 및 이의 용도

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/058036 WO2019083506A1 (en) 2017-10-24 2017-10-24 ANTI-GLYCO-MUC1 ANTIBODIES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237040745A Division KR102832078B1 (ko) 2017-10-24 2017-10-24 항-글리코-muc1 항체 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20200067885A KR20200067885A (ko) 2020-06-12
KR102608763B1 true KR102608763B1 (ko) 2023-11-30

Family

ID=66247577

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237040745A Active KR102832078B1 (ko) 2017-10-24 2017-10-24 항-글리코-muc1 항체 및 이의 용도
KR1020207014390A Active KR102608763B1 (ko) 2017-10-24 2017-10-24 항-글리코-muc1 항체 및 이의 용도

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020237040745A Active KR102832078B1 (ko) 2017-10-24 2017-10-24 항-글리코-muc1 항체 및 이의 용도

Country Status (10)

Country Link
EP (1) EP3700936A4 (OSRAM)
JP (2) JP7358367B2 (OSRAM)
KR (2) KR102832078B1 (OSRAM)
CN (1) CN111479828B (OSRAM)
AU (1) AU2017436815B2 (OSRAM)
BR (1) BR112020008001A2 (OSRAM)
CA (1) CA3078812A1 (OSRAM)
IL (1) IL274202A (OSRAM)
MX (1) MX2020004220A (OSRAM)
WO (1) WO2019083506A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020004220A (es) * 2017-10-24 2020-10-05 Go Therapeutics Inc Anticuerpos anti-glico-muc1 y sus usos.
AU2021316098A1 (en) * 2020-07-31 2023-03-16 R.P. Scherer Technologies, Llc Antibody specific for Mucin-1 and methods of use thereof
CA3230370A1 (en) * 2021-08-27 2023-03-02 Peptron, Inc. Novel anti-muc1 antibody and use thereof
CN118475617A (zh) * 2021-12-21 2024-08-09 美勒斯公司 针对与癌症相关的muc1的结合域
CN115068610B (zh) * 2022-01-27 2024-04-16 中国农业大学 抑制乳腺癌细胞中muc1表达的物质在降低抗乳腺癌药物耐药性中的应用
TW202444432A (zh) * 2023-04-13 2024-11-16 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｅｇｆｒ和ｍｕｃ１的抗原結合分子、其藥物偶聯物及其醫藥用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150005474A1 (en) * 2003-01-23 2015-01-01 Glycotope Gmbh Recognition molecules for the treatment and detection of tumors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020146750A1 (en) * 2000-03-30 2002-10-10 Hoogenboom Hendricus R.J.M. Mucin-1 specific binding members and methods of use thereof
EP2083868A2 (en) * 2006-10-04 2009-08-05 Københavns Universitet Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
EP2014302A1 (en) * 2007-07-12 2009-01-14 Institut Curie An antibody specific for the Tn antigen for the treatment of cancer
EP2221374A4 (en) * 2007-12-05 2011-01-19 Kyowa Hakko Kirin Co Ltd MONOCLONAL ANTIBODY CAPABLE OF BINDING TO A GROWTH FACTOR OF HB-EGF (HEPARIN-BINDING EPIDERMAL GROWTH FACTOR)
US8722856B2 (en) * 2008-10-28 2014-05-13 National University Corporation Hokkaido University Anti-MUC1 antibody
EP2281844A1 (en) * 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
US20170145108A1 (en) * 2014-02-05 2017-05-25 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
RU2016144178A (ru) * 2014-04-28 2018-05-10 Медисинал Кемистри Фармасьютикалс, Ко., Лтд. Антитело против muc1 или его антигенсвязывающий фрагмент и его применение
MX2020004220A (es) * 2017-10-24 2020-10-05 Go Therapeutics Inc Anticuerpos anti-glico-muc1 y sus usos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150005474A1 (en) * 2003-01-23 2015-01-01 Glycotope Gmbh Recognition molecules for the treatment and detection of tumors

Also Published As

Publication number Publication date
JP7358367B2 (ja) 2023-10-10
KR20200067885A (ko) 2020-06-12
EP3700936A4 (en) 2021-05-26
CA3078812A1 (en) 2019-05-02
JP2024001073A (ja) 2024-01-09
CN111479828B (zh) 2024-07-05
CN111479828A (zh) 2020-07-31
WO2019083506A1 (en) 2019-05-02
AU2017436815B2 (en) 2025-05-29
KR20230165874A (ko) 2023-12-05
EP3700936A1 (en) 2020-09-02
BR112020008001A2 (pt) 2020-10-20
KR102832078B1 (ko) 2025-07-08
JP2021510307A (ja) 2021-04-22
MX2020004220A (es) 2020-10-05
IL274202A (en) 2020-06-30
AU2017436815A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
US12065504B2 (en) Anti-glyco-MUC1 antibodies and their uses
US20230126689A1 (en) Anti-glyco-cd44 antibodies and their uses
KR102608763B1 (ko) 항-글리코-muc1 항체 및 이의 용도
US20250304716A1 (en) Anti-glyco-muc1 antibodies and their uses
US20250136701A1 (en) Anti-glyco-cmet antibodies and their uses
US20250066498A1 (en) Anti-glyco-lamp1 antibodies and their uses
US20250101126A1 (en) Anti-glyco-muc4 antibodies and their uses
US20250326855A1 (en) Anti-glyco-cd44 antibodies and their uses
CN118354788A (zh) 抗糖-muc4抗体及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601